FzioMed, Inc. Signs Distribution Agreement with DePuy AcroMed in Europe Leading Spine Company to Begin Selling FzioMed's Oxiplex®/SP Gel Adhesion Prevention Product in Europe

SAN LUIS OBISPO, California - July 8, 2002 - FzioMed, Inc., the developer of Oxiplex® technology, announced today it has signed a European distribution agreement with DePuy AcroMed, Inc.

FzioMed is engaged in the development and manufacture of advanced, absorbable biosurgery products. DePuy AcroMed, a Johnson & Johnson company, is a spine industry leader focused on the design, development, manufacturing and marketing of spinal products used by orthopedic surgeons and neurosurgeons worldwide.

Under the agreement, DePuy AcroMed will distribute FzioMed's Oxiplex/SP Adhesion Prevention Gel in Europe to orthopedic surgeons and neurosurgeons for use in spine surgical procedures such as laminectomy and discectomy. FzioMed will manufacture the product and provide sales support and training assistance.

Oxiplex/SP Gel is a bioabsorbable gel that is applied during spinal surgery to reduce post-operative internal scarring, also known as post-surgical adhesions. Post-surgical adhesions are a leading complication of many surgical procedures. FzioMed is also developing adhesion prevention products for pelvic/abdominal surgery, cardiac surgery and tendon surgery.

"We are very excited to have DePuy AcroMed, a premier company in the spinal products market, as a distribution partner for Oxiplex/SP Gel," said Ronald Haynes, President and CEO of FzioMed. "There is a great unmet need for an effective anti-adhesion product in spine surgery. We look forward to working with our partner to bring Oxiplex/SP to surgeons in Europe."

FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, absorbable biosurgery products based on the company's patented Oxiplex® technology. Oxiplex® is an innovative polymer technology that is formulated for a variety of targeted medical indications and markets. Products in development using Oxiplex® include those for the prevention of post-surgical adhesions, hemostasis during surgery, osteoarthritis and drug delivery. FzioMed products are at various stages of clinical and pre-clinical development in the United States and are directed towards high growth markets in the rapidly growing field of biosurgery products.

Oxiplex is a registered trademark of FzioMed, Inc.

Back to News Articles